Antihyperglycemic, antihyperlipidemic and antioxidative potential of fucoidan

M.A. Nagy1,*, S.A. Mohamed2
1Chemistry department, Faculty of science, Beni-Suef University, (EGYPT)  
2Biochemistry department, Faculty of Medicine, El Azher University, (EGYPT)  
E-mail: Nagy_bio@yahoo.com

ABSTRACT

Alloxan administration in male albino rats, induced diabetes by increasing blood glucose concentration and reducing hepatic glycogen content as compared to normal control group. Besides, serum lipid profile parameters such as total-cholesterol, triglyceride, low-density lipoprotein and very low-density lipoprotein cholesterol were also elevated, whereas, the level of high-density lipoprotein-cholesterol was reduced significantly (P<0.05) in diabetic rats. Treatment of diabetic animals with fucoidan for 30 days, significantly lowered blood glucose level, elevated hepatic glycogen content and maintained body weight and lipid-profile parameters towards near normal range.

Declined activity of antioxidant enzymes and concentration of non-enzymatic antioxidants were also normalized by drug treatment, thereby reducing the oxidative damage in the tissues of diabetic animals and hence indicating the anti-diabetic and antioxidant efficacy of fucoidan.

Biochemical observations were further substantiated with histological examination of pancreas and liver. © 2014 Trade Science Inc. - INDIA

INTRODUCTION

The increasing incidence of diabetes represents an enormous socio-economic burden in the developing countries. The World Heath Organization estimates that over 300 million people worldwide will have (Diabetes mellitus) DM by the year 2025 with alarming proportions from developing countries[1].

Oxidative stress represents a significant mechanism for the destruction of cells that can involve apoptotic cell injury and apoptosis in a variety of cell types that involve endothelial cells (ECs), cardiomyocytes, and smooth muscle cells through multiple cellular pathways. The production of Reactive oxygen species (ROS) can lead to cell injury through a number of processes that involve the peroxidation of cellular membrane lipids[2].

In recent years due to the adverse effects of synthetic hypoglycemic drugs, interests in alternate therapeutic approach have become very popular. Nowadays, herbal drugs are gaining popularity in the treatment of diabetes and its complications due to their efficacy, low incidence of side effects and low cost[3]. An
Increasing number of studies have demonstrated that certain compounds produced by marine organisms, including algae, have potential therapeutic uses.

Brown marine algae to be rich sources of antioxidants compounds with potential free radical scavenging for the prevention and treatment of various diseases caused by oxidative damage. Fucoidans, polysaccharides containing substantial percentages of L-fucose and sulfate ester groups, are constituents of brown algae that have numerous other biological properties such antioxidant, anti-inflammatory immunomodulatory and apoptosis-inducing activities. In the present study, the effect of 30 day chronic oral treatment with fucoidan with a dose of 0.02 g/kg body weight of rats daily on diabetes and resultant oxidative stress was investigated by evaluating its antihyperglycemic, antihyperlipidemic and antioxidative properties in alloxan induced diabetic rats confirmed by histological examination of Pancrea and liver of alloxan induced diabetic rats.

MATERIALS AND METHODS

Chemicals

Fucoidan procured from Sigma Chemical Co. (St. Louis, MO) was used in the study. Alloxan monohydrate was purchased from sigma Fine chemicals. All other chemicals used for this study were of analytical grade and obtained from Stanbio Laboratory USA Kits. Kits for the estimation of total cholesterol, triglyceride and HDL-cholesterol were purchased from Diamond Diagnostic Egypt.

Animal care and monitoring

Thirty healthy male albino rats (5-7 months old, weighing 190-210 g) were procured from Faculty of Agricultural, El Minia University, Egypt. They were housed under standard laboratory conditions of light (12:12 h L: D cycle), temperature (23 ± 2°C) and relative humidity (55 ± 5%). The animals were provided standard rat pellet feed and tap water ad libitum. Maintenance and treatment of all the animals was done in accordance with the principles of Institutional Animal Ethics Committee constituted as per the directions of the Committee for the Purpose of Control and Supervision of Experiments on Animals, Egypt.

Introduction of diabetes and treatment with drugs

For the present study, animals were divided into following 3 groups: NC (normal control), DC (diabetic control) and fucoidan (diabetic + fucoidan). After fasting for 18 hours, rats of group DC, fucoidan were made diabetic by a single intra-peritoneal injection of alloxan monohydrate, 150 mg/kg body wt, freshly dissolved in normal saline. Subsequent to alloxan administration the rats had free access to food and water and were provided with 50% glucose solution to drink overnight to counter drug induced hypoglycemic shock. One week after alloxan injection, the fasting blood glucose (FBG) concentration was determined by means of one touch ultra glucometer (Johnson & Johnson Company, USA) and compatible blood glucose strips. Rats showing fasting blood level greater than 140 mg/dl were considered diabetic and selected for treatment with fucoidan (0.02 g/kg body weight). Fucoidan were administered orally (0.02 g/kg body weight) once in a day for consecutive 30 days.

Biochemical estimations in blood and serum insulin

Fasting blood glucose (FBG) concentration of all the four experimental groups was determined by glucometer during different phases of the experiment by withdrawing blood from the tail vein. Serum insulin was assayed in the Radioactive Isotopes Unit, Central Department of Scientifical Analysis and Test, National Research Center (Dokki, Giza) by radioimmunoassay kits of DPC (Diagnostic Products Corporation, Los Angeles, USA). For estimating serum lipid profile, serum was isolated from the blood collected by cardiac puncture under mild ether anesthesia from overnight fasted rats on day 30th of fucoidan treatment and serum total cholesterol (TC), triglyceride (TG) and HDL-cholesterol were estimated by using diagnostic kits (Erba Mannheim Cholesterol kit, Transasia Bio-Medicals Ltd., Daman).

Biochemical estimation in tissue homogenates

Liver and pancreas were removed, freed from adhering tissues and washed with ice-cold normal saline solution (0.9%). Weight of all the organs was taken only after drying the tissue. 1 g tissue was homogenized in 10 ml of 0.2 M tris-HCl with the help of homogenizer. The homogenate was filtered and then centri-
fuged at 10,000 rpm for 20 minutes at 4°C. The supernatant obtained was used for estimation of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), reduced glutathione (GSH) thiobarbituric acid reactive substances (TBARS), Hepatic G-6-Pase and glycogen phosphorylase.

**Histopathological examination of tissues**

**Histopathological examination of pancreas**

Some pancreas were cleaned and fixed in 10% neutral buffered formalin solution. After dehydration in graded ethanol solutions and in toluene, they were embedded in paraffin. Sections of 3–5 µm thickness were stained with hematoxylin and eosin (H.E.) for histopathological examination.

**Histopathological examination of liver**

Some liver were cleaned and fixed in 10% neutral buffered formalin solution. After dehydration in graded ethanol solutions and in toluene, they were embedded in paraffin. Sections of 3–5 µm thickness were stained with hematoxylin and eosin (H.E.) for histopathological examination. Other sections were stained with (Periodic acid staining) PAS Stain and Trichome stain for histopathological examination of glycogen and collagen respectively.

**Statistical analysis**

Results are expressed as mean ± Standard Error of Mean (SEM). Statistical analysis was performed using one-way Analysis of Variance (ANOVA) followed by Tukey’s post-hoc multiple comparison test using SPSS (version 16.0) and student’s ‘t’-test using SigmaPlot (version 8.0). The values of P<0.05 were considered as statistically significant.

**RESULTS**

**Effect on body weight**

All animals treated with alloxan in diabetic control group (DC) revealed a significant (P<0.05) loss in body weight, which was persistently observed till the end of the study period (TABLE 1). Weight reduction induced by diabetes in group (fucoidan) was cured by fucoidan treatment.

**Effect on fasting blood glucose level and serum insulin**

Alloxan injection to DC and fucoidan groups resulted in a significant (P<0.05) increase in blood glucose level as compared to normal control group A. Treatment with fucoidan for 30 days significantly reduced the glucose after 30 days of treatment (TABLE 1).

**Effect of fucoidan on activity of hepatic glycogen phosphorylase and hepatic glucose-6- phosphatase in alloxan induced diabetic rats**

Activity of hepatic glycogen phosphorylase and hepatic glucose-6- phosphatase increased significantly in diabetic control group (DC) compared to normal control group (NC). However, treatment with fucoidan hot water extract for 30 days significantly (P<0.05) decreased activity of hepatic glycogen phosphorylase and hepatic glucose-6- phosphatase as compared to DC (TABLE 2).

**Effect on serum lipid profile**

Compared to normal control group (NC), the level of serum TC, TG, LDL cholesterol was significantly (P<0.05) increased whereas the level of HDL-cholesterol was significantly (P<0.05) reduced by in untreated diabetic rats (DC) (TABLE 3). After treatment of group f with ucoidan for 30 days, the level of serum TC, TG, and LDL -cholesterol reduced significantly (P<0.05)

---

**TABLE 1: Effect of 30 days treatment with fucoidan on body weight and FBG level in alloxan-induced diabetic rats. Values are mean ± SEM of 7 observations.**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>NC</th>
<th>DC</th>
<th>DC+fucoidan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body Weight (g)</td>
<td>190±12.2</td>
<td>165.2±11.3</td>
<td>257.5&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>FBG Level (mg/dl)</td>
<td>121.12±2.3</td>
<td>465±41.8&lt;sup&gt;***a&lt;/sup&gt;</td>
<td>255±18.9&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Serum insulin levels (ng/ml)</td>
<td>1.18±0.07</td>
<td>0.48±0.07&lt;sup&gt;***a&lt;/sup&gt;</td>
<td>1.12±0.07&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Values significantly different compared to normal P<0.01. Values are expressed as means ± SEM. Means not sharing common letter are; significantly different (p < 0.05).
TABLE 2: Effect of 30 days treatment with fucoidan on activity of hepatic glycogen phosphorylase and hepatic glucose-6-phosphatase (G6Pase) content in alloxan-induced diabetic rats. Values are mean ± SEM of 7 observations.

<table>
<thead>
<tr>
<th>Group</th>
<th>Hepatic glycogen phosphorylase (mU/g tissue)</th>
<th>Hepatic glucose-6-phosphatase (G6Pase) (mU/g tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Control (NC)</td>
<td>0.95±0.13</td>
<td>1.42±0.21</td>
</tr>
<tr>
<td>Diabetic Control (DC)</td>
<td>6.47±0.76 ***a</td>
<td>8.45±0.97 ***a</td>
</tr>
<tr>
<td>Diabetic+ fucoidan (DC + fucoidan)</td>
<td>3.9±0.39 b</td>
<td>4.67±0.41 b</td>
</tr>
</tbody>
</table>

Values significantly different compared to normal P*** * < 0.01. Values are expressed as means ± SEM. Means not sharing common letter are; significantly different (p < 0.05).

TABLE 3: Effect of 30 days treatment with fucoidan on serum lipid profile in alloxan-induced diabetic rats. Values are mean ± SEM of 7 observations.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>NC</th>
<th>DC</th>
<th>fucoidan</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>87.2±8.4</td>
<td>163.2±7.9 ***a</td>
<td>115.6±7.1 b</td>
</tr>
<tr>
<td>TG</td>
<td>74.2±6.8</td>
<td>178.2±10.4 ***a</td>
<td>135.5±9.4 b</td>
</tr>
<tr>
<td>HDL</td>
<td>63.2±5.7</td>
<td>39.3±4.5 ***a</td>
<td>43.2±4.1 b</td>
</tr>
<tr>
<td>LDL</td>
<td>13.5±7.3</td>
<td>53.2±4.8 ***a</td>
<td>35.2±3.0 b</td>
</tr>
</tbody>
</table>

Values significantly different compared to normal P*** * < 0.01. Values are expressed as means ± SEM. Means not sharing common letter are significantly different (p < 0.05).

whereas, the level of serum HDL-cholesterol was significantly increased.

Antioxidative status

It was observed that after inducing diabetes, the level of hepatic and pancreatic GSH content decreased significantly in diabetic control group (DC) as compared to normal control group (NC). Treatment of diabetic rats with fucoidan 30 days significantly (P<0.05) increased the tissue’s GSH level as compared to DC (TABLE 4).

Data of the present study also revealed a significantly (P<0.05) increased concentration of TBARS, a measure of lipid peroxidation, in the hepatic and pancreatic tissues of diabetic rats. However, a significant reduction in the level of TBARS was observed in the pancreas of fucoidan treated group (fucoidan) (TABLE 4). Induction of diabetes significantly (P<0.05) reduced the activity of catalase and GSH-Px in liver and pancreas of DC as compared to NC. However, 30 days treatment of diabetic animals with fucoidan increased the activity of these enzymes in pancreatic tissue only (TABLE 4). Alloxan injection significantly (P<0.05) decreased the activity of SOD in pancreas after 30 days treatment with fucoidan significantly improved the activity of SOD in the pancreas of fucoidan treated group (TABLE 4).

Effects of fucoidan on alloxan-induced histological changes in pancreas

The results of fucoidan in histopathologic examination are shown in Figure 1. As revealed in Figure 1b), a clear decrease in the area occupied by the β-cells was observed in the pancreatic sections of alloxan-induced diabetic rats. Treatment with fucoidan showed hypertrophy, hyperplasia and vacuolations of β-cells of islets of langerhans compared to alloxan treated rats (Figure 1c) revealing the protective effect of fucoidan.

Effects of fucoidan on alloxan-induced histological changes in liver (H&E Stain)

The results of fucoidan in histopathologic examina-
Figure 1.a: Pancreatic tissue of normal male albino rats. The pancreas is subdivided by septa in the pancreatic lobules. The exocrine portion of the pancreas consists of pancreatic acini while endocrine portion consists of islets of Langerhans (H&E x 400).

Figure 1.b: Pancreatic tissue of diabetic rats. Normal architecture of the islets is disrupted islets of Langerhans exhibited hydrophobic cells, necrotic cells, vacuolizations and irregular hyperchromic nuclei (H&E x 400).

Figure 1.c: Pancreatic tissue of diabetic rats treated with fucoidan (orally 0.02 g/kg body weight of rats daily for 30 consecutive days) showing hypertrophy, hyperplasia and vacuolations of β- cells of islets of langerhans (H&E x 400).

Figure 1: Histological changes in pancreases of diabetic rats (H&E)
tion are shown in Figure 2. As revealed in (Figure 2b) kupffer cells activation, dilation and congestion of central vein and hepatic sinusoids were observed in the hepatic sections of alloxan-induced diabetic rats. Treatment with fucoidan showed kupffer cells activation and congestion of central vein compared to alloxan treated rats (Figure 2c) revealing the hepatotoxic effect of fucoidan.

Effects of fucoidan on alloxan-induced histological changes in liver (PAS)

The results of fucoidan in histopathologic examination are shown in Figure 3. As revealed in (Figure 3b), variable sized positive Pas glycogen particles distributed throughout the hepatocytic cytoplasm in the hepatic sections of alloxan-induced diabetic rats. Treatment with fucoidan showed a moderate PAS particles distributed throughout the hepatocytic cytoplasm compared to alloxan treated rats (Figure 3c).

DISCUSSION

Glucose is the key physiological regulator of insulin secretion; indeed, short-term exposure of β-cells to increasing glucose concentrations induces proliferation in a concentration-dependent manner. In addition to its effect on β-cell turnover, hyperglycemia also impairs β-cell secretory function. This glucotoxic effect is evident before apoptosis leads to a significant decrease in β-cell mass[6].

Alloxan–induced diabetic rats exhibited severe glucose intolerance and metabolic stress as well as hyperglycemia due to a progressive oxidative insult interrelated with a decrease in endogenous insulin secretion and release. Treatment with antioxidative drugs based on their pancreatic antioxidant activity might be a protective strategy for protecting β-cell due to disproportionate generation of free radicals[7].

The present investigation indicated that a single dose of alloxan (150 mg/kg) intraperitoneally to adult male albino rats (190-210g) was suitable to induce histological changes of the islets of Langerhans characterized appearance, hypoinsulinemia and hyperglycemic state. The present dose as well as the observed histological and biochemical manifestations[8].

A gradual loss of β-cells due to apoptosis significantly hinders insulin production and inhibits cell viability. During apoptosis, cells shrink; chromatin condenses; DNA is cleaved into pieces at inter nucleosomal regions. A proactive way to increase β-cell viability is to decrease apoptosis level in order to retain the cell population and increase insulin production[9].

Exposure of islets to alloxan shows significantly increased formation of peroxynitrite, NO and ROS with markedly elevated lipid peroxidation and reduced cell viability. Islets exposed to alloxan also show significantly increased mitochondrial membrane potential. Apparently, alloxan causes severe oxidative and cytotoxic stress to islets that is likely to compromise their insulin releasing capacity[10].

Overproduction of ROS or exhaustion of antioxidants may cause oxidative stress which is a major factor of defective insulin secretion and increases apoptosis of pancreas[8]. Moreover, ROS produced by β-cell in response to metabolic stress affect mitochondrial structure and function and lead to β-cell failure. Specifically, ROS oxidize mitochondrial membrane phospholipids such as cardiolipin, which impairs membrane integrity and leads to cytochrome c release and apoptosis. In addition, ROS activate UCP2 via peroxidation of the mitochondrial membrane phospholipids, which results in proton leak leading to reduced ATP synthesis and content in β-cells[12].

However, continuous treatment of diabetic animals with fucoidan for 30 days caused a significant reduction in FBG level. This antihyperglycemic action may be due to sulphated polysaccharides from marine algae that are known to be important free-radical scavengers and antioxidants for the prevention of pancreatic oxidative damage, which is an important contributor in DM[13]. The observed depletion of liver glycogen stores in diabetic rats is consistent with an earlier study[14] indicating that it could be due to the loss of glycogen-synthesis activating system and/or increased activity of glycogen phosphorylase[15] since alloxan causes selective destruction of β-cells of the islets of langerhans resulting in a marked decrease of insulin levels, it is rational to believe that the activity of hepatic glycogen phosphorylase and hepatic glucose-6- phosphatase of diabetic animals will increased, as synthesis of glycogen depends on insulin for the influx of glucose. However, previous studies show that the reduced activity of gly-
Figure 2.a: Liver of normal control rat showing the normal histological structure of hepatic lobule (H&E x 400).

Figure 2.b: Liver of diabetic rat showing kupffer cells activation, dilation and congestion of central vein and hepatic sinusoids (H&E x 400).

Figure 2.c: Liver section of diabetic rats treated with fucoidan (orally 0.02 g/kg body weight of rats daily for 30 consecutive days) showing kupffer cells activation and congestion of central vein (H&E x 400).

Figure 2: Histological changes in liver of diabetic rats (H&E).
Figure 3.a: Liver of normal control rat showing accumulation of reddish stained glycogen particles at one pole of hepatocytes (PAs stain x 400).

Figure 3.b: Liver of alloxan induced diabetic rat showing variable sized positive Pas glycogen particles distributed throughout the hepatocytic cytoplasm (PAs stain x 400)

Figure 3.c: Liver of diabetic rats treated with fucoidan (orally 0.02 g/kg body weight of rats daily for 30 consecutive days) showing no histological changes (PAs stain x 400)

Figure 3: Histological changes in liver of diabetic rats (PAS):
cogen phosphorylase and hepatic glucose-6-phosphatase hepatic by insulin treatment[16]. Administration of fucoidan for 30 days also showed a trend towards a significant increase in glycogen content when compared to diabetic rats, thus confirming its insulin potentiating effect to a certain extent.

The antihyperglycemic efficacy of fucoidan can be correlated with the findings of previous study[17]. Similarly, alloxan caused body weight loss was also regained to its above-initial values by fucoidan treatment, which reflects an improved health of fucoidan treated animals.

The histological observation of the pancreatic tissues further substantiates the claim that fucoidan has a protective nature on pancreatic tissue.

The characteristic features of diabetic dyslipidemia are a high plasma triglyceride concentration, low HDL-cholesterol concentration and increased concentration of small dense LDL-cholesterol particles. Faulty glucose utilization causes hyperglycemia and mobilization of fatty acids from adipose tissue for energy purpose. The lipid changes associated with diabetes mellitus are attributed to increased flux of free fatty acids into the liver secondary to insulin deficiency/resistance. This results in excess fatty acid accumulation in the liver, which is converted to triglycerides. The impaired ability of insulin to inhibit free fatty-acid release leads to elevated hepatic VLDL-cholesterol production. The increased VLDL-cholesterol and triglyceride levels decrease the level of HDL-cholesterol and increase the concentration of small dense LDL-cholesterol particles by activation of lipoprotein lipase and lecithin acyl-cholesterol transferase.

In our study, elevated levels of serum TC, TG and LDL cholesterol and decreased HDL cholesterol concentration in alloxan-induced diabetic rats. However, treatment with fucoidan normalized all the lipid profile parameters. This antihyperlipidemic attributed to fucoidan that enhance the negative charges of cell surface so as to effect the aggradation of cholesterol in blood, thus decreasing the cholesterol in serum[18]. Earlier it has been explored that oxidative stress forms the foundation for the induction of multiple cellular pathways that can ultimately lead to both the onset and subsequent complications of DM. Diabetics and experimental animal models exhibit high oxidative stress due to persistent and chronic hyperglycemia, which thereby depletes the activity of antioxidative defense system and thus promotes de novo free radicals generation.

GSH oxidation is a major contributor to cell apoptosis mediated by oxidants. Accumulated evidence from our laboratory has consistently shown that an early spike in GSSG formation, typically within minutes of oxidant exposure, preceded oxidant-induced activation of mitochondrial apoptotic signaling and cell apoptosis hours later.

In our study, the level of hepatic and pancreatic GSH was reduced in diabetic rats, which is consistent with an earlier report[19]. The decrease in tissue’s GSH content could be the result of decreased synthesis or increased degradation of GSH by oxidative stress that prevails during diabetes[20].

In the present study, along with decreased level of reduced GSH, a marked increase in the concentration of TBARS was also observed in liver and pancreas of diabetic mice; however, treatment of these animals with fucoidan decreased the elevated level of TBARS. Simultaneously, reduced GSH content was also increased significantly which indicates that the fucoidan can either increase the biosynthesis of GSH and/or reduce the oxidative stress that ultimately reduces the degradation of GSH. Similar results were also witnessed in an earlier study[21]. Catalase is a common enzyme found in nearly all living organisms. Its functions include catalyzing the decomposition of hydrogen peroxide to water and oxygen. One of the most commonly used ROS for neuronal oxidative stress preconditioning is H2O2. It is formed by the dismutation of superoxide (O2) spontaneously or enzymatically in a reaction that is catalyzed by superoxide dismutase (SOD). H2O2 is less reactive compared to other ROS, easily crosses membranes, and diffuses from its original site of production.

Many more studies documented a pivotal role for H2O2 in the development of vascular dysfunction in pathological conditions, such as atherosclerosis, hypertension, and diabetes mellitus. It has also been speculated that, in the vessel wall, H2O2-mediated mechanisms may compensate for the loss of NO-mediated dilation during the development of various diseases[22].

To prevent damage, it must be quickly converted into other, less dangerous substances. To this end, catalase is frequently used by cells to rapidly catalyze the
decomposition of hydrogen peroxide into less reactive gaseous oxygen and water molecules. Superoxide dismutases are a class of enzymes that catalyze the dismutation of superoxide into oxygen and hydrogen peroxide. As such, they are an important antioxidant defense in nearly all cells exposed to oxygen.

However, fucoidan therapy increased the activity of CAT and GSH-Px in pancreatic tissues of treated diabetic animals\(^{[13]}\). Reductone-associated sulphonyl groups of polysaccharides can act as electron donors and can react with free radicals to convert these polysaccharides to more stable products and thereby terminate radical chain reactions\(^{[23]}\).

The increased activity of CAT, SOD and GSH-Px suggest a compensatory response to oxidative stress as it reduces the endogenous H2O2 produced thus diminishing the toxic effects due to this radical or other free radicals derived from secondary reactions\(^{[24]}\).

However, the level of Hepatic TBARS, Hepatic GSH and activity of antioxidant enzymes in hepatic tissue of diabetic rats was not improved by fucoidan treatment. This perhaps is due to different metabolic actions of the tissues and their different responses to oxidative stress or the hepatotoxic nature of the fucoidan.

The histological observation of the hepatic tissues further substantiates the claim that fucoidan has a toxic nature on hepatic tissue.

From the results obtained, it can be concluded that fucoidan possess significant antihyperglycemic, antihyperlipidemic and pancreatic antioxidative properties. Hence, apart from controlling hyperglycemia it would also be beneficial in the alleviation of associated diabetic complications including the prevention of the development of atherosclerosis and other coronary artery diseases. However, further studies are needed to investigate and elucidate the possible mechanism of action of the active ingredients, establish complete safety profiles and evaluate the potential value of fucoidan for the management of diabetes and hyperlipidemia in the clinic.

Moreover, additional parameters such as assay of fructosamine, HbA1c, C-peptide etc should also be studied. This may prove helpful for developing new drugs from this plant for managing diabetes and associated complications.

ACKNOWLEDGEMENT

Authors gratefully acknowledge Vice Chancellor, El Minia, for the financial support through the Department of Agriculture chemistry.

REFERENCES


\[3\] K.A.Amin, M.A.Nagy; Effect of carnitine and herbal mixture extract on obesity inducedby high fat diet in rats. Diabetol Metab Syndr,16, 1(1), 17 (2009).


\[7\] N.S.El-Shenawy, I.M.Abdel-Nabi; Hypoglycemic effect of Cleome droserifolia ethanolic leaf extract in experimental diabetes, and on non-enzymatic antioxidant, glycogen, thyroid hormone and insulin levels. Diabetologia Croatica, **35**, 15-22 (2006).


